| 000 | 01699 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250513084350.0 | ||
| 264 | 0 | _c19960226 | |
| 008 | 199602s 0 0 eng d | ||
| 022 | _a0887-6924 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWielenga, J J | |
| 245 | 0 | 0 |
_aRecombinant human interleukin-3 (rH IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase I/II study. _h[electronic resource] |
| 260 |
_bLeukemia _cJan 1996 |
||
| 300 |
_a43-7 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Controlled Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibiotics, Antineoplastic _xadministration & dosage |
| 650 | 0 | 4 |
_aAntimetabolites, Antineoplastic _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 |
_aCytarabine _xadministration & dosage |
| 650 | 0 | 4 |
_aDaunorubicin _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterleukin-3 _xadministration & dosage |
| 650 | 0 | 4 |
_aLeukemia, Myeloid, Acute _xblood |
| 650 | 0 | 4 | _aLeukocyte Count |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMitoxantrone _xadministration & dosage |
| 650 | 0 | 4 | _aPlatelet Count |
| 650 | 0 | 4 |
_aRecombinant Proteins _xadministration & dosage |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aRemission Induction |
| 700 | 1 | _aVellenga, E | |
| 700 | 1 | _aGroenewegen, A | |
| 700 | 1 | _aSonneveld, P | |
| 700 | 1 | _aLöwenberg, B | |
| 773 | 0 |
_tLeukemia _gvol. 10 _gno. 1 _gp. 43-7 |
|
| 999 |
_c8558010 _d8558010 |
||